bioAffinity Technologies (BIAFW) Net Margin (2022 - 2026)

bioAffinity Technologies has disclosed Net Margin across 5 years of filings, most recently posting 268.63% for Q1 2026.

• In Q1 2026, Net Margin fell 12510.0% year-over-year to 268.63%; the TTM figure through Mar 2026 stood at 280.57% (down 17002.0% YoY), while the FY2025 annual figure was 241.96%, down 14541.0% from the prior year.
• Net Margin fell to 268.63% in Q1 2026, from 196.98% in the prior quarter.
• Over the last five years, Net Margin for BIAFW reached as high as 81.53% in Q1 2024 and fell as low as 427778.96% in Q3 2022.
• The 5-year median for Net Margin is 294.25% (2025), against an average of 42730.41%.
• The widest YoY moves for Net Margin: up 42701145 bps in 2023, down 207425 bps in 2023.
• A 5-year view of Net Margin shows it stood at 71380.35% in 2022, then surged by 100 bps to 107.22% in 2023, then fell by 25 bps to 134.4% in 2024, then plunged by 47 bps to 196.98% in 2025, then tumbled by 36 bps to 268.63% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 268.63%, 196.98%, and 349.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.